Abstract
Background Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need for effective treatments for progressive disease. We assessed the efficacy of pembrolizumab for patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer. Methods We did this randomised, open-label, phase 2/3 study at 202 academic medical centres in 24 countries. Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells were randomly assigned (1:1:1) in blocks of six per stratum with an interactive voice-response system to receive pembrolizumab 2 mg/kg, pembrolizumab 10 mg/kg, or docetaxel 75 mg/m2 every 3 weeks. The primary endpoints were overall survival and progression-free survival both in the total population and in patients with PD-L1 expression on at least 50% of tumour cells. We used a threshold for significance of p
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1540-1550 |
| Number of pages | 11 |
| Journal | The Lancet |
| Volume | 387 |
| Issue number | 10027 |
| DOIs | |
| State | Published - Apr 9 2016 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010) : A randomised controlled trial. / Herbst, Roy S.; Baas, Paul; Kim, Dong Wan; Felip, Enriqueta; Pérez-Gracia, José L.; Han, Ji Youn; Molina, Julian R; Kim, Joo Hang; Arvis, Catherine Dubos; Ahn, Myung Ju; Majem, Margarita; Fidler, Mary J.; De Castro, Gilberto; Garrido, Marcelo; Lubiniecki, Gregory M.; Shentu, Yue; Im, Ellie; Dolled-Filhart, Marisa; Garon, Edward B.
In: The Lancet, Vol. 387, No. 10027, 09.04.2016, p. 1540-1550.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010)
T2 - A randomised controlled trial
AU - Herbst, Roy S.
AU - Baas, Paul
AU - Kim, Dong Wan
AU - Felip, Enriqueta
AU - Pérez-Gracia, José L.
AU - Han, Ji Youn
AU - Molina, Julian R
AU - Kim, Joo Hang
AU - Arvis, Catherine Dubos
AU - Ahn, Myung Ju
AU - Majem, Margarita
AU - Fidler, Mary J.
AU - De Castro, Gilberto
AU - Garrido, Marcelo
AU - Lubiniecki, Gregory M.
AU - Shentu, Yue
AU - Im, Ellie
AU - Dolled-Filhart, Marisa
AU - Garon, Edward B.
PY - 2016/4/9
Y1 - 2016/4/9
N2 - Background Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need for effective treatments for progressive disease. We assessed the efficacy of pembrolizumab for patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer. Methods We did this randomised, open-label, phase 2/3 study at 202 academic medical centres in 24 countries. Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells were randomly assigned (1:1:1) in blocks of six per stratum with an interactive voice-response system to receive pembrolizumab 2 mg/kg, pembrolizumab 10 mg/kg, or docetaxel 75 mg/m2 every 3 weeks. The primary endpoints were overall survival and progression-free survival both in the total population and in patients with PD-L1 expression on at least 50% of tumour cells. We used a threshold for significance of p
AB - Background Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need for effective treatments for progressive disease. We assessed the efficacy of pembrolizumab for patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer. Methods We did this randomised, open-label, phase 2/3 study at 202 academic medical centres in 24 countries. Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells were randomly assigned (1:1:1) in blocks of six per stratum with an interactive voice-response system to receive pembrolizumab 2 mg/kg, pembrolizumab 10 mg/kg, or docetaxel 75 mg/m2 every 3 weeks. The primary endpoints were overall survival and progression-free survival both in the total population and in patients with PD-L1 expression on at least 50% of tumour cells. We used a threshold for significance of p
UR - http://www.scopus.com/inward/record.url?scp=84950117835&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84950117835&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(15)01281-7
DO - 10.1016/S0140-6736(15)01281-7
M3 - Article
C2 - 26712084
AN - SCOPUS:84950117835
VL - 387
SP - 1540
EP - 1550
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 10027
ER -